Skip to main content
. 2017 Mar 17;8(24):38731–38742. doi: 10.18632/oncotarget.16317

Figure 8. Effect of daily systemic treatment of PTC 209 in different forms on tumor growth.

Figure 8

Syngeneic mice were implanted in the 4th mammary pad of FVB animals with mouse CSC, FMMC 419II at 0.75×106 cells per implant. Animals were treated daily at 1 mg/Kg, subcutaneously, with free PTC 209, PLGA-PEG encapsulating PTC 209 (PTC 209 NP), or PLGA-PEG conjugated with anti-CD49f and encapsulating PTC 209 (Anti-CD49f PTC 209 NP) as compared to vehicle control or void PLGA-PEG NPs. Data represent mean ± S.D., n = 5/group, *P <0.05 versus control or void NPs, ** P <0.01 versus all arms.